Position in ASND
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$3,520,154
+$44,342 QoQ
Shares Held
15,390
-5.6% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ASND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Calamos Advisors LLC holds $103,200,124 across 23 Biotechnology names. ASND ranks #7 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
77,886 | $34,779,214 | |
| 2 | RPRX |
Royalty Pharma plc
|
437,090 | $20,967,207 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,793 | $9,111,743 | |
| 4 | INSM |
INSMED Inc
|
36,373 | $5,947,712 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
73,600 | $4,756,768 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
20,860 | $4,164,698 | |
| 7 | ASND |
Ascendis Pharma A/S
This page
|
15,390 | $3,520,154 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
43,832 | $3,074,814 |
All Filings in ASND
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,520,154 | 15,390 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $3,475,812 | 16,300 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $1,282,324 | 6,450 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||